Background Patients with SLE experience distressing fibromyalgia-like symptoms of fatigue, widespread pain, mood disturbance, and brain fog that negatively impact quality of life and are challenging ...

Results 293 visits from 124 patients were included, 116 (93.5%) were women with a mean age at diagnosis of 35.2 (12.6) years. Mean CQR at baseline was 75.9 (13.6) and at the end of follow-up was 76.4 ...

Objective This systematic review seeks to survey existing literature concerning systemic lupus erythematosus (SLE)-related thrombosis risk mechanisms within six pro-coagulable categories: ...

Objectives This study aimed to derive and validate a cut-off for severe disease activity (SDA) using the SLE Disease Activity Score (SLE-DAS) and compare its accuracy and impact on health-related ...

Background Single-cell RNA-sequencing (scRNA-seq) has been recently applied in systemic lupus erythematosus (SLE) to define distinct cellular composition and transcriptional signatures, greatly ...

Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis. Phase II studies have shown promising results, although long-term data are ...

The significant allelic effect at rs13385731 and enhancer effect on RasGrp3 expression level. (A) ChIP-qPCR assays for determining allele-specific DNA-protein interactions with H3K27ac, H3K4me1, ...

Objective The heterogeneity of lupus clinical manifestations makes it difficult to precisely characterize the full spectrum of patient profiles with traditional real-life (claims) data sources. This ...

Background Proliferative lupus nephritis (LN) is characterized by robust glomerular and tubulo- interstitial inflammation, sub-endothelial deposits of immunoglobulin, and increased endothelial cell ...

Objective Patients with SLE have a well-known increased risk of major comorbidities, although they are also very heterogeneous in terms of the prevalence of comorbid conditions. The relationships of ...

Background People with SLE (and their doctors) are concerned about the risk of COVID-19 infection, yet some patients still harbor concerns regarding vaccination. The first mRNA SARS-CoV-2 vaccines ...

Background Abnormalities of type I interferon signaling and production can initiate lupus development. Disturbances of nucleic acid-sensing molecules triggered autoreactivity in lupus mouse models.